Given our recent findings that HER2-mediated radioresistance of breast cancer is initiated by radiation via NF-κB activation, blocking the NF-κB/HER2 network, including many mediators/effectors of the network, will be a crucial approach for sensitizing resistant breast cancer cells to radiotherapy. Here, NFKB1 is linked to breast carcinoma.